Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Binnopharm Group.

    Client Virtual Booth

    BINNOPHARM GROUP

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Binnopharm Group
    Russia-big Flag
    Country
    Country
    Russia
    Address
    Address
    14 Kozhevnicheskaya St., Bld. 5, Moscow, 115114
    Telephone
    Telephone
    +7 (495) 646-28-68
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://en.binnopharmgroup.ru/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Mabwell Bioscience Partners with Binnopharm Group to Market 9MW0113, 9MW0321 and 9MW0311 in Russia and Eurasian Economic Union Countries

    Details:

    Junmaikang (adalimumab) is a biosimilar of Humira, Junmaikang was approved in China for Rheumatoid arthritis, ankylosing spondylitis, Psoriasis, Crohn's disease, uveitis, polyarticular juvenile idiopathic arthritis and Crohn's disease in children.


    Lead Product(s): Adalimumab

    Therapeutic Area: Immunology Product Name: Junmaikang

    Highest Development Status: ApprovedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Mabwell Bioscience

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement December 20, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Binnopharm Group Enters Into Agreement to Acquire Two Anti-Bacterial Brands From Dr. Reddy’s in the Russia & CIS Region

    Details:

    Deal will allow Binnopharm Group to acquire anti-bacterial medicines under the Ciprolet® and Levolet® brands from Dr. Reddy’s in Russia, Uzbekistan and Belarus. The portfolio includes various dosage forms such as tablets, solution for infusions and eye drops.


    Lead Product(s): Ciprofloxacin

    Therapeutic Area: Infections and Infectious Diseases Product Name: Ciprolet

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition February 21, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-05-06

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search